Latest Insider Transactions at Oncotelic Therapeutics, Inc. (OTLC)
This section provides a real-time view of insider transactions for Oncotelic Therapeutics, Inc. (OTLC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Oncotelic Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Oncotelic Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 23
2024
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
500,000
+0.54%
|
$0
$0.02 P/Share
|
|
Jun 29
2023
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
425,000
+0.46%
|
$0
$0.02 P/Share
|
|
Jun 28
2023
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
75,000
+0.08%
|
$0
$0.03 P/Share
|
|
Jun 16
2023
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+0.11%
|
$0
$0.03 P/Share
|
|
Jun 14
2023
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
400,000
+0.44%
|
$0
$0.03 P/Share
|
|
May 26
2023
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
126,888
+0.14%
|
$0
$0.03 P/Share
|
|
May 02
2023
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+0.11%
|
$0
$0.04 P/Share
|
|
Dec 06
2022
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
120,000
+0.13%
|
$0
$0.05 P/Share
|
|
Nov 22
2022
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
70,000
+0.08%
|
$0
$0.08 P/Share
|
|
Sep 26
2022
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
20,000
+0.02%
|
$0
$0.07 P/Share
|
|
Aug 25
2022
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
80,000
+0.09%
|
$0
$0.08 P/Share
|
|
Jul 08
2021
|
Amit B. Shah CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
298,837
+45.44%
|
-
|
|
Jul 08
2021
|
Saran Saund Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
102,519
+0.62%
|
-
|
|
Jul 08
2021
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
259,302
+0.29%
|
-
|
|
Mar 31
2021
|
Saran Saund Chief Business Officer |
BUY
Conversion of derivative security
|
Direct |
16,354,961
+50.0%
|
-
|
|
Mar 31
2021
|
Steven W King Director |
BUY
Conversion of derivative security
|
Indirect |
3,291,720
+49.71%
|
-
|
|
Mar 31
2021
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Conversion of derivative security
|
Indirect |
19,521,186
+45.22%
|
-
|
|
Mar 31
2021
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Conversion of derivative security
|
Direct |
74,455,719
+45.2%
|
-
|
|
Mar 31
2021
|
Anthony E Maida Iii Chief Clin. Ops. Officer |
BUY
Conversion of derivative security
|
Direct |
938,646
+45.22%
|
-
|
|
Nov 24
2020
|
Amit B. Shah CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
8,220
+12.05%
|
$0
$0.19 P/Share
|
|
Nov 23
2020
|
Amit B. Shah CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
20,088
+27.95%
|
$0
$0.19 P/Share
|
|
Nov 20
2020
|
Amit B. Shah CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
31,692
+50.0%
|
$0
$0.2 P/Share
|
|
Nov 19
2020
|
Vuong Trieu CHAIRMAN AND CEO |
BUY
Open market or private purchase
|
Direct |
50,500
+0.32%
|
$0
$0.19 P/Share
|
|
Nov 19
2020
|
Chulho Park CHIEF TECHNOLOGY OFFICER |
BUY
Open market or private purchase
|
Direct |
22,173
+0.78%
|
$0
$0.18 P/Share
|